Roche acquiring P&G's stake in U.S. OTC joint venture covering Aleve, Femstat 3.
This article was originally published in The Tan Sheet
ROCHE GAINING SOLE RIGHTS TO OTC ALEVE AND FEMSTAT 3 under an agreement with Procter & Gamble announced by the companies June 27. Roche Holding Ltd. will acquire P&G's 50% interest in the company's U.S. Rx-to-OTC switch joint venture with Syntex. P&G, which has dedicated considerable marketing resources to the two switch products -- over $100 mil. to launch Aleve -- reports that it will see a "$120 mil. after-tax gain" in the fourth quarter as a result of the sale. However, P&G says the sale of its stake in the joint venture will provide a greater return than would continued marketing of the products.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC